目的：探讨玻璃体切除(PPV)术前辅助应用抗血管内皮生长因子(VEGF)药物(康柏西普)对增殖性糖尿病视网膜病变(PDR)患者玻璃体液中炎症细胞因子水平的影响。

方法：收集2017-06/2018-01于南京医科大学第一附属医院眼科就诊并确诊的PDR患者49例49眼，随机分为两组，no-IVC组患者25例25眼PPV术前未接受玻璃体腔注射治疗，IVC组患者24例24眼PPV术前5～7d接受玻璃体腔注射康柏西普治疗。纳入患者均于PPV术前收集玻璃体液样本，并采用Luminex液相悬浮芯片技术检测血管内皮生长因子A(VEGF-A)、单核细胞趋化因子(MCP-1)及炎症细胞因子的水平。

结果：与no-IVC组相比，IVC组患者玻璃体液中VEGF-A水平显著降低(P<0.001)，炎症细胞因子IL-6(P=0.004)、IL-8(P=0.002)、IL-18(P=0.04)、TNF-α(P=0.03)水平显著升高，其余炎症细胞因子水平均无显著差异。

结论：PPV术前辅助玻璃体腔注射康柏西普可有效降低PDR患者玻璃体液中VEGF-A水平，但对炎症细胞因子水平的影响有限。

METHODS: A total of 49 patients(49 eyes)who diagnosed with PDR at the First Affiliated Hospital with Nanjing Medical University from June 2017 to January 2018 were recruited and randomly divided into two groups. A total of 25 cases(25 eyes)who did not receive intravitreal injection before PPV were included in no-intravitreal injection of Conbercept(IVC)group, and 24 cases(24 eyes)who received IVC 5～7d before PPV were included in IVC group. The vitreous samples were collected from all the patients at the start of PPV. Levels of VEGF-A, monocyte chemotactic protein-1(MCP-1)and inflammatory cytokines in the vitreous humor were measured using Luminex technology.

RESULTS: Compared with the no-IVC group, the level of VEGF-A decreased significantly(P<0.001), the concentration of IL-6(P=0.004), IL-8(P=0.002), IL-18(P=0.04)and TNF-α(P=0.03)increased remarkably in the IVC group. The other inflammatory cytokines in the vitreous humor showed no significant difference between the IVC and no-IVC groups.

CONCLUSION: IVC before PPV can effectively decrease the concentration of VEGF-A, but had limited influence on the level of inflammatory cytokines in the vitreous humor of patients with PDR.